Its indications were initially only CTCL and expanded to PTCL in November 2011, and the objective response rate was 34% in CTCL patients and 25% in patients with PTCL.449 Moreover, tucidinostat (chidamide), containing pyridine and N-(2-amino-5-fluorophenyl)-benzamide groups, is a benzamide inhibitor of HDAC1/2/3/10. The gene discussed is HDAC1; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.